Evidence map›Paper›PMID 22492485›Full record

ArticleDiabetes/metabolism research and reviews2012

Performance of a multi-marker diabetes risk score in the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort.

Michael W Rowe, Richard N Bergman, Lynne E Wagenknecht, Janice A Kolberg

Abstract readMulticenter Study
In one paragraph

Article in Diabetes/metabolism research and reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael W RoweTethys Bioscience, Inc., Emeryville, CA 94608, USA.
Richard N Bergman
Lynne E Wagenknecht
Janice A Kolberg
Tethys Research (United States) · USCedars-Sinai Medical Center · USWake Forest University · US

Funding

QUANTITATION OF FACTORS REGULATING GLUCOSE TOLERANCER01DK029867 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MARILYN ADER · 1986 to 2026
$11.0M
Quantitative Studies of Metabolic Organ DynamicsR37DK027619 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERGMAN, RICHARD NATHAN · 2007 to 2016
$6.2M
NIDDK NIH HHS R01 DK029867NIDDK NIH HHS R37 DK027619
6 · The paper itself

Abstract

backgroundThis study compares a previously developed Diabetes Risk Score to commonly used clinical tools for type 2 diabetes risk evaluation in the Insulin Resistance Atherosclerosis Study (IRAS) cohort, a multi-ethnic US cohort. Available as a clinical test, the PreDx® Diabetes Risk Score uses fasting concentrations of adiponectin, C-reactive protein, ferritin, interleukin-2 receptor alpha, HbA(1c) , glucose and insulin, plus age and gender to predict 5-year risk of diabetes. It was developed in a Northern European population.

methodsThe Diabetes Risk Score was measured using archived fasting plasma specimens from 722 non-diabetic IRAS participants, 17.6% of whom developed diabetes during 5.2 years median follow-up (inter-quartile range: 5.1-5.4 years). The study included non-Hispanic whites (41.8%), Hispanics (34.5%) and African Americans (23.7%). Performance of the algorithm was evaluated by area under the receiver operating characteristic curve (AROC) and risk reclassification against other tools.

resultsThe Diabetes Risk Score discriminates participants who developed diabetes from those who did not significantly better than fasting glucose (AROC = 0.763 versus 0.710, p = 0.003). The Diabetes Risk Score performed equally well in subpopulations defined by race/ethnicity or gender. The Diabetes Risk Score provided a significant net reclassification improvement of 0.24 (p = 0.01) when comparing predefined low/moderate/high Diabetes Risk Score categories to metabolic syndrome risk factor counting. The Diabetes Risk Score complemented the use of the oral glucose tolerance test by identifying high risk patients with impaired fasting glucose but normal glucose tolerance, 33% of whom converted.

conclusionsMeasuring the Diabetes Risk Score of elevated-risk US patients could help physicians decide which patients warrant more intensive intervention. The Diabetes Risk Score performed equally well across the ethnic subpopulations present in this cohort.

Indexed as

AdultAgedBlack or African AmericanBlood GlucoseCohort StudiesC-Reactive ProteinDiabetes Mellitus, Type 2EthnicityFemaleGlucose Tolerance TestHispanic or LatinoHumansInsulin ResistanceMaleMetabolic SyndromeMiddle AgedBlood GlucoseC-Reactive Protein

Identifiers

PMID22492485
PMCPMC5931211
OpenAlexW2120346598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.